Exosomes, small extracellular vesicles secreted by cells, have emerged as focal mediators in intercellular communication and therapeutic interventions across diverse biomedical fields. Inflammatory disorders, including inflammatory bowel disease, acute liver injury, lung injury, neuroinflammation, and myocardial infarction, are complex conditions that require innovative therapeutic approaches. This review summarizes recent advances in exosome-based therapies for inflammatory disorders, highlighting their potential as diagnostic biomarkers and therapeutic agents. Exosomes have shown promise in reducing inflammation, promoting tissue repair, and improving functional outcomes in preclinical models of inflammatory disorders. However, further research is needed to overcome the challenges associated with exosome isolation, characterization, and delivery, as well as to fully understand their mechanisms of action. Current limitations and future directions in exosome research underscore the need for enhanced isolation techniques and deeper mechanistic insights to harness exosomes’ full therapeutic potential in clinical applications. Despite these challenges, exosome-based therapies hold great potential for the treatment of inflammatory disorders and may offer a new paradigm for personalized medication.
Induced neural stem cells (iNSCs), which have similar properties to neural stem cells and are able to self-proliferate and differentiate into neural cell lineages, are expected to be potential cells for the treatment of neurodegeneration disease. However, cell therapy based on iNSCs transplantation is limited by the inability to acquire sufficient quantities of iNSCs. Previous studies have found that mouse and human fibroblasts can be directly reprogrammed into iNSCs with a single factor, Sox2. Here, we induced mouse embryonic fibroblasts (MEFs) into iNSCs by combining valproic acid (VPA) with the induction factor Sox2, and the results showed that VPA significantly improved the conversion efficiency of fibroblasts to iNSCs. The iNSCs exhibited typical neurosphere-like structures that can express NSCs markers, such as Sox2, Nestin, Sox1, and Zbtb16, and could differentiate into neurons, astrocytes, and oligodendrocytes in vitro. Subsequently, the iNSCs were stereotactically transplanted into the hippocampus of APP/PS1 double transgenic mice (AD mice). Post-transplantation, the iNSCs showed long-term survival, migrated over long distances, and differentiated into multiple types of functional neurons and glial cells in vivo. Importantly, the cognitive abilities of APP/PS1 mice transplanted with iNSCs exhibited significant functional recovery. These findings suggest that VPA enhances the conversion efficiency of fibroblasts into iNSCs when used in combination with Sox2, and iNSCs hold promise as a potential donor material for transplantation therapy in Alzheimer’s disease.
Inhibition of carbonic anhydrases (EC 4.2.1.1, hCAs) is known to be a potential target for treatment of several disorders like epilepsy, glaucoma, obesity, and cancer. The current research focuses on the synthesis of a series of 4’-amino-[1,1’-biphenyl]-4-sulfonamide derivatives (9a-e) through cross-coupling reactions in the presence of Cu(OAc)2 catalyst. The structural elucidation of synthesized derivatives was carried out through1H NMR, and13C NMR. These sulphonamide derivatives were screened for inhibitory potential towards various isozymes of carbonic anhydrases including hCA-II, hCA-IX, and hCA-XII. Enzyme inhibition assay exhibited that synthesized derivatives with IC50 ± SEM, 9e (0.38 ± 0.03µM), 9d (0.21 ± 0.03 µM) and 9b (0.69 ± 0.15 µM) had remarkable inhibition potency against hCA-II, hCA-IX and hCA-XII respectively. It was noted that 9d exhibited 8-fold more inhibitor potential as compared to standard inhibitor acetazolamide. For the most potent inhibitors, enzyme kinetic analysis was also carried out to find inhibition mode. Furthermore, the drug-ability of synthesized compounds was evaluated through SwissADME tools, and found that all the newly prepared derivatives successfully satisfied the drug-ability criteria. Molecular docking studies were conducted to identify the types of interactions between the synthesized ligands and the target proteins.